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charge a fee of R35.00 for this service. CONCLUSIONS: PIT is an important service 
that pharmacists deliver where the need exists. It is recommended that pharmacists be 
encouraged to counsel patients thoroughly when delivering a PIT service.
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OBJECTIVES: To examine drug cost containment policy implemented at a hospital in 
southern Thailand. METHODS: This study was a retrospective, pre-post policy inter-
vention descriptive design. During the ﬁ scal years of 2005 and 2009, various drug cost 
containment strategies, including generic substitution for any drug group and a success-
ful treatment guideline for orthopedic drugs, were adopted at a hospital in southern 
Thailand. Drug expenditures across those ﬁ scal years were examined. The expenditure 
proportions between drugs listed and unlisted in National Essential Drug List were 
calculated. Cost-saving analysis of all generic substitution was conducted. Since the 
treatment guideline for orthopedic drugs was available in the hospital, their expenditures 
were also examined. RESULTS: Total drug expenditures had increased with decreasing 
rate across the study years. It increased by 47.15% from year 2005 to 2006, 43.19% 
from year 2006 to 2007, 21.17% from year 2007 to 2008 and 2.17% from year 2008 
to 2009. The expenditures of essential drugs in the National Drug List were accounted 
for 61.64%, 56.62%, 54.38%, 48.67% and 50.94% across those study periods, respec-
tively. Results showed that generic drug substitution policy reduced overall drug expen-
ditures by 34.33%, or 7.66 million baths from year 2008. In 2009, only 11 items of 
generic drug substitution for branded-name drugs could reduce drug expenditures by 
13.33%, or 4.73 million bahts which reﬂ ected annual cost-saving about 25.95 million 
bahts. In the same year, a result showed that the implementation of orthopedic drug 
guideline reduced drug expenditures by 5.53% or 2.10 million bahts. CONCLUSIONS: 
The study indicated that treatment guideline and generic drug substitution policies could 
control relatively high amount of drug expenditures at a hospital in southern Thailand. 
Hospital administrators should consider to continue these policies.
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OBJECTIVES: The aim of this study was to asess the annual health insurance reim-
bursement of of dental health service in Hungary. METHODS: The assessment base 
of the study was the annual reports of National Health Insurance Fund Administration 
(OEP). Only the data collected from the services in conctractual relationship with the 
OEP and delivered in 2008 were evaluated. Dental care services are organised in dif-
ferent levels: general dental service, specialist dental care, special dental care on uni-
versity level and inpatient departments. Our study covers primary, outpatient and 
hospital dental care. RESULTS: Dental care was supplied by 3378 general and special-
ist dental care services until the end of 2008. For the hospital treatment of more serious 
cases 17 inpatient department is available with 154 patient beds. Within the period 
of examination (2008) 7.6 million cases or rather 23.6 million interventions were 
carried out. The health insurance expenditures of the OEP for outpatient dental care 
was 23.9 billion forints (c85,18 million). The total health insurance reimbursement 
of dental care (including primary, outpatient and hospital care) was 24.92 billion 
Hungarian forints (c88.82 million) in 2008. CONCLUSIONS: The health insurance 
reimbursement of dental care services in Hungary is approximately 2% of the total 
health insurance expenditure of OEP.
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OBJECTIVES: There is a known concern of health researchers and public managers in 
Brazil with the population’s access to medicines. We quantiﬁ ed the public expenditure 
on medicines in Brazil, during the period of 2005 to 2008. METHODS: The expenditure 
on medicines comes from a data warehouse of the Ministry of Planning, Budget and 
Management that stores the information concerning any purchase made by the Brazilian 
Federal Government. We also computed the amounts transferred to ofﬁ cial laboratories 
to produce medicines. Information on the states, Federal District and municipalities 
came from the Information System on Public Health Budget (SIOPS). RESULTS: In the 
period 2005 to 2008, the public spending with drugs rose from US$ 1.8 billion to US$ 
2.0 billion in real terms, with an average annual growth equivalent to 3%. The average 
spending in this period was US$ 1.8 billion. Most of the spending on medicines is 
attributed to the Federal Government, with values exceeding US$ 835 million per year. 
Just under half of the expenditure is given to states and municipalities. Considering only 
the federal spending, the “strategic component” represents the largest share, with par-
ticipation from 56%–64% in the period. This result is expected, since the Ministry of 
Health is responsible for funding all the medicines from the “strategic component” of 
pharmaceutical care which includes, among others, the antiretroviral drugs and blood 
products. The amounts of transfers to ofﬁ cial laboratories ranged between 20–25% of 
drug costs. CONCLUSIONS: The expenditure for those pharmaceutical care programs 
whose purchases are centralized at the federal Ministry of Health, didn’t show a signiﬁ -
cant increase in the period of 2005–2008. Rather, the evidence suggests relative stability 
of procurement of medicines from pharmaceutical care programs under the Federal 
Government’s responsibility in this period.
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OBJECTIVES: The aim of our study is to calculate the average health insurance reim-
bursement of spa treatment according to counties in Hungary. METHODS: Data were 
derived from the Hungarian National Health Insurance Fund Administration (OEP) and 
covers the ﬁ scal year of 2007. These data was analyzed in the light of different value of 
its average point. The Hungarian spa ﬁ nancing method is based on relative system, 
which is depending on the treatment’s price. We calculated the average health insurance 
subsidy per of spa treatment (HIS/STN) as an indicator of average health insurance 
reimbursement of a single spa treatment. RESULTS: In 2007 the number of spa treat-
ment was 8,160,438 and the full treatment expenditure of subsidy was 4.34 billion HUF 
(US$25,632 million). The average value of (HIS/STN) was 540,000 HUF (US$3124). 
Two outlier points are the region of North Hungarian Plan (different from average HIS/
STN value was −6.76%) and region of North Transdanubia (different from average 
HIS/STN value was 12.47%). The other regions performed similar outcomes ratio 
between 1.33% and 2.95%. CONCLUSIONS: The main cause of the two outlier 
regions is the inadequat structure of Spa services. Less people visit to North Transda-
nubian Region, because the number of spa facilities isn’t signiﬁ cant, but these thermal 
baths are signiﬁ cant, which price is higher. The North Hungarian Plan attracts a lot of 
patients with lower price. The result if the price is lower, the subsidy will be lower 
because of the ﬁ nancing system is based on relative method.
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OBJECTIVES: Achieving Market Access for new products has become complex for 
pharmaceutical companies. Faced with growing expenditure, health care authorities 
accept or propose various Market Access Agreements (MAA) (risk-sharing/perfor-
mance-based/commercial schemes) but often with little experience and knowledge. We 
performed in-depth analysis of their design and we formulate recommendations to 
stakeholders. METHODS: MAA is a formalized compromise between payers and 
industry to achieve: Price and Reimbursement, HTA recommendation and Formulary 
listing. We reviewed published and grey literature from major health insurers in 
France, Italy, Germany and UK. We conceptualize MAA typology according to the 
nature of uncertainty perceived by stakeholders and their motivations. RESULTS: We 
identiﬁ ed above 30 MAAs and classiﬁ ed them as follows: 1) Value for money not 
questioned: a) Conditional Market Access Agreement: Evidence development 
agreement→Aim: address actual uncertainty; b) Health Outcome Boostering Agree-
ment: Disease Management Initiative→Aim: improve competitive advantage; 2) Value 
for money questioned: a) Cost Containment Agreement: Basic commercial 
agreement→Aim: reduce/control drug bill; b) Health Outcomes Agreement: Value 
based agreement→Aim: link payment to performance. Motivations of public payers: 
Main: Buy health production; Other: Control expenditure; Improve ICER of expensive 
products; Prevent media coverage of negative decision; Provide patient access; Expand 
beneﬁ ts basket. Motivations of the industry: Main: Achieve Market Access for a 
product at high price in all markets; Other: Mitigate development failure; Reassure 
share holders; Improve company publicity; Fulﬁ l requirements of authorities. In UK 
the design of MAA was a direct consequence of formalized HTA, in Italy there was 
no apperent rationale. CONCLUSIONS: Commonly used nomenclature needs to be 
revisited. Applying our typology framework should allow health care payers and the 
industry to design and implement MAAs rationally and with transparence. MAAs in 
UK are a direct repercussion of a not favorable primary HTA.
PHP62
VALUE OF CONGRESS ABSTRACTS OF COST-EFFECTIVENESS STUDIES 
FOR DECISION MAKERS
Karray S1, Jaroslawski S1, Dzbek J2, Altin S3, Gerber A3, Toumi M4
1Creativ Ceutical, Paris, Ile de France, France; 2Jagiellonian University, Kraków, Małopolskie, 
Poland; 3Institute for Quality and Efﬁ ciency in Health Care (IQWiG), Cologne, Germany; 
4University of Lyon, Lyon, France
OBJECTIVES: ISPOR, iHEA, and HTAi regularly organize congresses in the ﬁ eld of 
health economics. Given the number of abstracts accepted each year it is crucial to assess 
their credibility and how results of cost-effectiveness analyses differ across meetings. 
METHODS: We collected all abstracts published 2007–2009 at ISPOR (International 
and Europe), HTAi and iHEA meetings. Abstracts on cost comparison, cost of treat-
ment, cost beneﬁ t, cost consequences, cost-effectiveness, cost minimization and cost 
utility analyses were reviewed in depth according to a reading grid which allowed 
extraction of essential information that could enable evidence-based decision-making in 
health policy. This included e.g. availability of key methodological parameters, involve-
ment of the industry in authorship and details of conclusions. RESULTS: We analyzed 
5488 abstracts from ISPOR, 1410 from HTAi and 1969 from iHEA. Our preliminary 
